SYRE vs WST
Spyre Therapeutics, Inc. vs West Pharmaceutical Services — AI-powered side-by-side comparison
SYRE
Spyre Therapeutics, Inc.
67
Insufficient Data
VS
WST
West Pharmaceutical Services
74
Buy
| Metric | SYRE | WST |
|---|
| AI Score |
67
|
74
|
| Price |
$102.72
|
$351.74
|
| P/E Ratio |
-52.69×
|
44.65×
|
| ROE |
-21.7%
|
15.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
0.0%
|
36.8%
|
| Debt / Equity |
0.00×
|
0.10×
|
| Dividend Yield |
0.0%
|
0.3%
|
| RSI (14) |
53.3
|
58.0
|
| Beta |
3.026
|
1.138
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for SYRE versus WST.
WST leads by 7 points.
WST scores 74/100 (Buy) versus SYRE at 67/100 (Insufficient Data).
SYRE Committee View
100% agreement
3 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 77 -- overbought on the larger timeframe too — Technical
WST Committee View
100% agreement
5 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical